P Prokocimer

Summary

Publications

  1. doi request reprint Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial
    Philippe Prokocimer
    Trius Therapeutics Inc, 6310 Nancy Ridge Dr, Ste 104, San Diego, CA 92121, USA
    JAMA 309:559-69. 2013
  2. pmc Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections
    P Prokocimer
    Trius Therapeutics, Inc, 6310 Nancy Ridge Drive, Suite 105, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 55:583-92. 2011
  3. pmc Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment
    S Flanagan
    Cubist, San Diego, California, USA
    Antimicrob Agents Chemother 58:6471-6. 2014
  4. pmc In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions
    S Flanagan
    Trius Therapeutics, Inc, San Diego, California, USA
    Antimicrob Agents Chemother 57:3060-6. 2013
  5. pmc Tedizolid population pharmacokinetics, exposure response, and target attainment
    S Flanagan
    Cubist, San Diego, California, USA
    Antimicrob Agents Chemother 58:6462-70. 2014

Collaborators

Detail Information

Publications5

  1. doi request reprint Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial
    Philippe Prokocimer
    Trius Therapeutics Inc, 6310 Nancy Ridge Dr, Ste 104, San Diego, CA 92121, USA
    JAMA 309:559-69. 2013
    ..Increasingly, ABSSSIs are associated with drug-resistant pathogens, and many antimicrobial agents have adverse effects restricting their use. Tedizolid phosphate is a novel oxazolidinone in development for the treatment of ABSSSIs...
  2. pmc Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections
    P Prokocimer
    Trius Therapeutics, Inc, 6310 Nancy Ridge Drive, Suite 105, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 55:583-92. 2011
    ..9 liters (35.7%). Results of this study show a high degree of efficacy at all three dose levels without significant differences in the safety profile and support the continued evaluation of TP for the treatment of cSSSI in phase 3 trials...
  3. pmc Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment
    S Flanagan
    Cubist, San Diego, California, USA
    Antimicrob Agents Chemother 58:6471-6. 2014
    ..This study has been registered at ClinicalTrials.gov under registration numbers NCT01452828 [renal study] and NCT01431833 [hepatic study].). ..
  4. pmc In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions
    S Flanagan
    Trius Therapeutics, Inc, San Diego, California, USA
    Antimicrob Agents Chemother 57:3060-6. 2013
    ..gov as NCT01539473 (tyramine interaction study conducted at Covance Clinical Research Center, Evansville, IN) and NCT01577459 (pseudoephedrine interaction study conducted at Vince and Associates Clinical Research, Overland Park, KS)...
  5. pmc Tedizolid population pharmacokinetics, exposure response, and target attainment
    S Flanagan
    Cubist, San Diego, California, USA
    Antimicrob Agents Chemother 58:6462-70. 2014
    ..5 μg/ml. These findings support 200-mg tedizolid once daily as the optimum dose for treatment of ABSSSI. ..